AstraZeneca inks a cardio drug development pact with mRNA specialist Moderna
AstraZeneca has come back to the table to ink a new collaboration deal with the messenger RNA biotech Moderna.
Already a significant partner and investor in the unicorn biotech, AstraZeneca struck a deal to set up a program with Moderna on relaxin, looking to coax cells into producing a protein that could have a tonic effect on heart disease.
That’s a tall order, as cardio remains one of the toughest and most demanding fields in biopharma. Back in March Novartis was forced to concede that its big Phase III for serelaxin — a recombinant form of the relaxin-2 hormone — failed a big Phase III.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.